News | December 21, 2024
Merck closes license agreement for LM-299
Merck will record a pre-tax charge relating to the upfront payment of $588 million
Merck will record a pre-tax charge relating to the upfront payment of $588 million
Demonstrates vision gains with extended treatment intervals in retinal vein occlusion
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
Strengthening focus in Alzheimer's disease and neuroscience pipeline
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
The share subscription agreements are being executed at a pre-money equity value of US$ 1.65 billion
Akums Drugs will undertake this development and commercialization in India
Aims to achieve CDMO sales of US$ 400 million by 2028
Both the products are Gadolinium based Magnetic Resonance Imaging (MRI) contrast agents and will be the first set of contrast agent products in Zydus’ injectable portfolio for the US market
The recent inspection covered both cGMP and PAI processes
Subscribe To Our Newsletter & Stay Updated
